[1] Howlader, N., et al. (2014). US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Journal of the National Cancer Institute, 106(5), dju055.[2]中国抗癌协会/中华医学会肿瘤学分会乳腺癌诊疗指南与规范（2025年版 精要本).[3]中国临床肿瘤学会（CSCO）乳腺癌诊疗指南2024.[4]廖瑜玲.乳腺癌患者内分泌治疗依从性的影响因素分析[J].实用预防医学,2020,27(10):1229-1232.[5]McCowan C, Wang S, Thompson AM, et al.The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer, 2013, 109(5): 1172-1180.
